MedTrace Logo

Evaluation of Baroreflex Activation Therapy in Patients With Advanced Heart Failure

NCT03230643 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2020-08-07

No results posted yet for this study

Summary

The objective of this single center prospective clinical trial is to evaluate the safety and efficacy of carotid Baroreflex Activation Therapy (BAT) in advanced heart failure (HFrEF). Beyond that, the primary aim of this study is to identify patients of the whole HFrEF population that are most likely to benefit from this new promising therapy.

Conditions

Interventions

DEVICE

Barostim neo implantation

The Barostim neo Implantation is a new promising treatment option for patients with advanced heart failure (HEFrEF) as it might improve cardiac and vascular function by restoring sympathovagal-balance through its effects on the autonomic nervous system. In this observational study, data from patients who have received the Barostim neo System as part of clinical routine will be collected and analyzed. The implantation of this new device is not part of the study.

Sponsors & Collaborators

  • Heart and Diabetes Center North-Rhine Westfalia

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-01
Primary Completion
2019-10-15
Completion
2020-05-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03230643 on ClinicalTrials.gov